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Abstract
BACKGROUND: During recent years, a correlation
between the presence of antibodies in sera against
p53 and survival has been reported. The aim of the
present study was to analyze anti-p53 antibodies in
sera from patients with non small cell lung cancer
(NSCLC) prior to thoracic surgery and their correlation
to survival, nodal involvement, and tumor volume.
PATIENTS AND METHODS: Serum samples from 58
patients with NSCLC admitted to the Department of
Pulmonary Medicine in Uppsala were collected be-
tween 1993 and 1995 and analyzed for the expression
of anti-p53 antibodies. RESULTS: Antibodies against
p53 were detected in 12 patients (21%). No association
was found between increased levels of anti-p53 anti-
bodies and tumor volume (P = .84). There was a
numerical trend towards higher levels of anti-p53
antibodies in patients without nodal disease, when
compared with patients with nodal involvement,
although not statistically significant (P = .136). How-
ever, when patients with metastatic disease were
included, statistically significantly lower levels of
anti-p53 antibodies were demonstrated, in compari-
son to patients without any sign of nodal engagement
or metastatic disease (P = .038). Anti-p53 antibodies
and survival showed no correlation between increas-
ing index levels of anti-p53 antibodies and survival
(P = .18). Neither was a correlation found between
using the cutoff (>1.1) described by the manufacturer
and survival. CONCLUSION: The presence of anti-p53
antibodies was correlated neither to survival nor to
tumor volume in the present study. However, patients
with either nodal or metastatic disease had lower
levels of anti-p53 antibodies in comparison to patients
without signs of either nodal or metastatic disease.
These issues are discussed.
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Introduction
Lung cancer causes approximately 1 million deaths each
year [1]. Lung cancer is divided into non small cell lung
cancer (NSCLC) and small cell lung cancer (SCLC) due to
histological differences. Treatment of early limited NSCLC is
based on surgery, that is, if the patient is willing to undergo
surgery and is physically fit to withstand surgery. If not, the
patient is offered radiotherapy and/or chemotherapy based
on the staging of the tumor and the performance status of the
individual patient.
The p53 suppressor gene is implicated in the control of
the cell cycle, DNA synthesis, and DNA repair as well as
apoptosis [2]. If a mutation occurs within the p53 gene,
these functions might be disturbed. Antibodies against p53
can be detected in sera from cancer patients, and a
correlation between the expression of anti-p53 antibodies
and mutations within the p53 gene has been established [3].
Several studies have been conducted in which the presence
of p53 antibodies has been correlated to various clinical
parameters. In a previous study [4] by our group, we
demonstrated that the presence of p53 antibodies in sera
could predict increased survival if expressed before the start
of radiotherapy.
Because tumor size is probably associated with a greater
amount of p53 antigen in vivo, the immune system might be
more efficient in inducing an immune response. Thus, a
larger tumor size could be associated with increased anti-
body response to p53. In the present study, we have
focused on the index levels of anti-p53 antibodies prior to
thoracic surgery and their correlation to survival, and, fur-
ther, on the issue if a correlation exists between increasing
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index levels of anti-p53 antibodies and increased tumor
volume.
Patients and Methods
Serum samples from patients with NSCLC admitted to the
Department of Pulmonary Medicine in Uppsala were col-
lected between 1993 and 1995 prior to thoracic surgery. All
patients gave informed consent prior to collection of blood
samples and the samples were stored at 20jC until ana-
lyzed. The study was reviewed and approved by the
research ethical committee (no. 02-010) of the Uppsala
University (Uppsala, Sweden). The following clinical param-
eters were studied: age, gender, performance status, weight
loss, histopathology, tumor volume, lymph node involvement
according to pathology records or from reevaluation from CT
scans in conjunction with thoracic surgery, relapse, and
survival. The primary tumor volume was reevaluated and
measured by an experienced radiologist. Estimations were
reevaluated in 62% of the materials from CT scans whereas
the other cases were measured from pulmonary X-rays. The
calculations regarding tumor volume were performed using
the following formula: 4pX radiusY radiusZ radius/3.
Unfortunately, in three cases, tumor volume measurements
could not be performed due to missing data.
Anti-p53 Antibody Investigation
Blood was collected in 7-ml serum tubes without addi-
tive (367609; Becton Dickinson, Rutherford, NJ). A sand-
wich ELISA, commercially available from Dianova
(Hamburg, Germany), was utilized to measure the pres-
ence of anti-p53 antibodies from the sera. The measure-
ments were performed according to the manufacturer’s
instructions and the procedure has previously been
reported [5]. Briefly, human recombinant p53 is bound to
microtiter plates. Standards and samples were pipetted
into the wells. After incubation and washing, a horseradish
peroxidase–conjugated polyclonal goat antihuman IgG
was added. After incubation and washing, a chromogenic
substrate was added and the color intensity was measured
at 450 nm in a Titertek Multiskan (Edinburgh, Scotland). A
relative index for patients’ sera was calculated, according to
Table 1. Description of Patients and Their Correlation to Index Levels of Anti-p53 Antibodies.
TNM Class Number of
Patients
Mean
(Index Value of
Anti-p53 Antibodies)
Median
(Index Value of
Anti-p53 Antibodies)
Squamous
Cell
Carcinoma
Adenocarcinoma Other
Histology
Weight
Reduction
(%)
Tumor
Volume
I 37 1.3 0.1 16 19 2 11.1 51.4
II 3 0.2 0.0 0 3 0 33.3 75.7
IIIa 10 1.9 0.0 5 5 0 44.4 32.7
IIIb 2 0.3 0.3 0 1 1 0 53.3
IV 2 0.1 0.1 0 1 1 50.0 50.9
Not determined 4 0.4 0.03 0 3 1 0 167.0
Total 58 1.2 0.04 21 32 5 17.8 57.5
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Figure 1. Anti-p53 antibodies and survival according to cutoff (>1.1).
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manufacturer’s instructions, as follows: E450 (sample)
E450 (low control)/E450 (high control) E450 (low control).
The ELISA assays were performed without knowledge of
clinical data.
Statistics
The survival functions were estimated with the Kaplan-
Meier product– limit method and the median survival time
was estimated with linear interpolation of the survival func-
tion. Cox regression analysis was applied to study if certain
factors had an impact on survival. In cases where there was
only one dichotomous explanatory factor, the results from
the Cox analysis were the same as from the log-rank test.
Kruskal-Wallis test was applied to study differences between
groups. Throughout this study, a 5% significance level is
used in the statistical tests.
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Figure 2. Survival according to index values of anti-p53 antibodies.
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Figure 3. Index values of anti-p53 antibodies in patients with or without nodal involvement.
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Results
The median age of the patients was 64 years (39–80) and
the majority of patients (63%) were men. Almost all patients
were smokers or ex-smokers (84%). The majority of the
patients were classified as having performance status 0-I
(Table 1). Involuntary weight loss was found in 18% of the
patients. In 54 patients (93%), surgical resection was micro-
scopically radical. In three of those patients in which surgical
resection was not microscopically radical, these patients
received postoperative radiation.
Antibodies against p53 were detected in 12 of 58 (21%).
Twenty-four percent of the men and 14% of the women
expressed anti-p53 antibodies. Those patients expressing
the autoantibodies had a median index value of 5.66
(1.56–8.07).
Minimal follow-up was performed up to 3 years. After
3 years, 23 patients (40%) were alive. Patient characteristics
and their distribution of anti-p53 antibodies are shown in
Table 1.
No correlation was found between the index values of
anti-p53 antibodies and tumor volume; neither was any
correlation found between relapse and index values of anti-
p53 antibodies. The distribution according to histology is
shown in Table 1. Using the manufacturer’s cutoff, no
survival difference was found between patients with index
levels of anti-p53 >1.1 or <1.1 (Figure 1). Neither were
increasing index values of anti-p53 antibodies correlated to
survival (Figure 2). There was a numerical trend towards
higher levels of anti-p53 antibodies in patients without
nodal disease, when compared with patients with nodal
involvement, although not statistically significant (P = .136)
(Figure 3). However, when patients with metastatic disease
were included, there were statistically significantly lower
levels of anti-p53 antibodies in comparison with patients with
TN0M0 (P = .038) (Figure 4).
Discussion
In the majority of cases, lung cancer is associated with a poor
prognosis. After treatment, surveillance is founded on symp-
toms and chest X-rays. Today, no reliable serological tumor
marker has been established, although a number of bio-
logical markers (TPA, NSE, SCC, Cyfra 21-1, and CEA)
have been investigated regarding their potential as tumor
markers [6].
Anti-p53 antibodies have been extensively studied
because it has been shown that anti-p53 antibodies corre-
late to the mutational status of the p53 gene [3]. In a
previous study [4] by our group, we found that patients with
NSCLC expressing antibodies against p53 prior to radiation
therapy had a prolonged survival in comparison with those
patients who did not express anti-p53 antibodies. Studies
regarding resectable NSCLC patients have focused on
whether or not anti-p53 antibodies in sera are associated
with survival. In a study by Mitsudomi et al. [7], tumor
material and sera were collected in relation to thoracic
surgery from 188 patients with NSCLC. They concluded
that the incidence of antibodies against p53 was positively
associated with tumor stage and p53 overexpression but not
with survival. In another study, in which 84 patients with
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Figure 4. Index values of anti-p53 antibodies in patients with metastatic or nodal disease in comparison with patients without nodal involvement or
metastatic disease.
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resectable NSCLC were studied in relation to thoracic
surgery, the authors [8] found that patients with antibodies
against p53 had a lower probability of overall and disease-
free survival. Similar data were presented by Mack et al. [9].
They investigated 99 NSCLC patients with different stages
and found that anti-p53 antibodies mainly were found in
patients with advanced disease and that anti-p53 antibodies
were associated with a poorer prognosis. Further, Sangraj-
rang et al. [10] investigated 133 lung cancer patients and
found that the incidence of anti-p53 antibodies was higher in
patients with more advanced disease (stages III and IV). In
the present study, serum samples were collected prior to
thoracic surgery and the clinical courses of the patients
were followed for a minimum of 3 years after surgery. The
index levels ranged between 0.0 and 8.07 and, when using
cutoffs recommended by the manufacturer, we found that
21% of the patients in our study overexpressed antibodies
against p53 (Figure 1). We did not find a correlation
between increasing anti-p53 antibody index values or sur-
vival. Neither did we find survival differences according to
the defined cutoff (>1.1) (Figures 1 and 2). These data
support the findings by Mitsudomi et al. [7]. Secondary aims
of the study were to investigate if index levels of anti-p53
antibodies correlate with the primary tumor volume. Intui-
tively, an increased tumor volume should result in increased
amounts of tumor antigens, which in turn would activate the
immune system. Nevertheless, in the present study, tumor
volume was not associated with index values of anti-p53
antibodies (P = .83). However, a reduction of index levels of
anti-p53 antibody titers was demonstrated in patients with
nodal and metastatic disease (P = .038) (Figures 3 and 4).
One hypothetical explanation might be that some tumors
might produce cytokines that induce expression of CD 95-L
in the lymphocytes, resulting in initiation of apoptosis in
these lymphocytes, whereby the tumor counteracts the
response of the immune system [11]. Further, patients with
large tumors generally have a suppressed immune system
and thus might be incapable of producing significant
amounts of antibodies to counteract the disease [12].
Another hypothetical explanation might be that because
these serum samples are not collected from the immediate
surroundings of the tumor, the index values of anti-p53
antibodies amounts measured might only partly reflect the
immune response because there is a possibility that the
majority of antibodies might have reacted with their antigen
and thus are not detectable in sera [13].
In summary, data concerning the prognostic and predic-
tive information regarding anti-p53 antibodies diverge and
reflect rather the complex nature of NSCLC then a ‘‘true’’
tumor marker potential; however, further studies addressing
the impact different therapies have on index levels are
needed. In conclusion, the value of anti-p53 antibodies in
patients with NSCLC, in conjunction with thoracic surgery,
was not associated with either tumor volume or survival in
the present study.
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